These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22650242)

  • 1. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.
    Merk D; Steinhilber D; Schubert-Zsilavecz M
    Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marine sponge steroids as nuclear receptor ligands.
    Fiorucci S; Distrutti E; Bifulco G; D'Auria MV; Zampella A
    Trends Pharmacol Sci; 2012 Nov; 33(11):591-601. PubMed ID: 23000093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR).
    Mehlmann JF; Crawley ML; Lundquist JT; Unwalla RJ; Harnish DC; Evans MJ; Kim CY; Wrobel JE; Mahaney PE
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5289-92. PubMed ID: 19683924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
    Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
    Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.
    Merk D; Steinhilber D; Schubert-Zsilavecz M
    Expert Opin Drug Discov; 2014 Jan; 9(1):27-37. PubMed ID: 24261510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay.
    Han KC; Kim JH; Kim KH; Kim EE; Seo JH; Yang EG
    Anal Biochem; 2010 Mar; 398(2):185-90. PubMed ID: 19913492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: (Thematic Issue: medicinal chemistry of Farnesoid X Receptor (FXR) modulators: the-state-of-the-art).
    Marinozzi M
    Curr Top Med Chem; 2014; 14(19):2127-8. PubMed ID: 25388532
    [No Abstract]   [Full Text] [Related]  

  • 12. Farnesoid X receptor agonists in biliary tract disease.
    Fiorucci S; Baldelli F
    Curr Opin Gastroenterol; 2009 May; 25(3):252-9. PubMed ID: 19300246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists.
    Lamers C; Schubert-Zsilavecz M; Merk D
    Curr Top Med Chem; 2014; 14(19):2188-205. PubMed ID: 25388533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X receptor modulators: a patent review.
    Crawley ML
    Expert Opin Ther Pat; 2010 Aug; 20(8):1047-57. PubMed ID: 20569093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.
    Fiorucci S; Mencarelli A; Distrutti E; Palladino G; Cipriani S
    Curr Med Chem; 2010; 17(2):139-59. PubMed ID: 19941473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
    Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
    J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Synthetic ligands for nuclear receptors].
    Kato S
    Nihon Rinsho; 2010 Oct; 68(10):1830-4. PubMed ID: 20954325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
    Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M
    Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
    De Marino S; Festa C; Sepe V; Zampella A
    Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.